XVIVO Perfusion AB's share warrant program 2014/2016 is fully subscribed. A total of 195,000 warrants with the right to subscribe for new shares were issued. Each warrant has in June 2016 the right to subscribe for one new share at a price of SEK 58.60.
The annual shareholder meeting April 29, 2014 approved the warrant program of a maximum of 195,000 warrants to be offered to all employees in XVIVO Perfusion AB. Upon full exercise of the warrants, the share capital increase is SEK 5,000 corresponding to a dilution of about 1 percent of the total number of shares and votes.
Magnus Nilsson, CEO of XVIVO Perfusion: “The broad support is very encouraging and it gives all of our employees a stronger shareholder interest and an even stronger incentive to fulfill our goals.”
July 7, 2014
Gothenburg
XVIVO Perfusion AB (publ)